Dynamin impacts homology-directed repair and breast cancer response to chemotherapy

Sophia B. Chernikova, Rochelle B. Nguyen, Jessica T. Truong, Stephano S. Mello, Jason H. Stafford, Michael P. Hay, Andrew Olson, David E. Solow-Cordero, Douglas J. Wood, Solomon Henry, Rie von Eyben, Lei Deng, Melanie Hayden Gephart, Asaithamby Aroumougame, Claudia Wiese, John C. Game, Balázs Győrffy, J. Martin Brown

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

After the initial responsiveness of triple-negative breast cancers (TNBCs) to chemotherapy, they often recur as chemotherapy-resistant tumors, and this has been associated with upregulated homology-directed repair (HDR). Thus, inhibitors of HDR could be a useful adjunct to chemotherapy treatment of these cancers. We performed a high-throughput chemical screen for inhibitors of HDR from which we obtained a number of hits that disrupted microtubule dynamics. We postulated that high levels of the target molecules of our screen in tumors would correlate with poor chemotherapy response. We found that inhibition or knockdown of dynamin 2 (DNM2), known for its role in endocytic cell trafficking and microtubule dynamics, impaired HDR and improved response to chemotherapy of cells and of tumors in mice. In a retrospective analysis, levels of DNM2 at the time of treatment strongly predicted chemotherapy outcome for estrogen receptor–negative and especially for TNBC patients. We propose that DNM2-associated DNA repair enzyme trafficking is important for HDR efficiency and is a powerful predictor of sensitivity to breast cancer chemotherapy and an important target for therapy.

Original languageEnglish (US)
Pages (from-to)5307-5321
Number of pages15
JournalJournal of Clinical Investigation
Volume128
Issue number12
DOIs
StatePublished - Dec 3 2018

Fingerprint

Dynamins
Breast Neoplasms
Dynamin II
Drug Therapy
Triple Negative Breast Neoplasms
Microtubules
Neoplasms
DNA Repair Enzymes
Estrogens
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Chernikova, S. B., Nguyen, R. B., Truong, J. T., Mello, S. S., Stafford, J. H., Hay, M. P., ... Martin Brown, J. (2018). Dynamin impacts homology-directed repair and breast cancer response to chemotherapy. Journal of Clinical Investigation, 128(12), 5307-5321. https://doi.org/10.1172/JCI87191

Dynamin impacts homology-directed repair and breast cancer response to chemotherapy. / Chernikova, Sophia B.; Nguyen, Rochelle B.; Truong, Jessica T.; Mello, Stephano S.; Stafford, Jason H.; Hay, Michael P.; Olson, Andrew; Solow-Cordero, David E.; Wood, Douglas J.; Henry, Solomon; von Eyben, Rie; Deng, Lei; Gephart, Melanie Hayden; Aroumougame, Asaithamby; Wiese, Claudia; Game, John C.; Győrffy, Balázs; Martin Brown, J.

In: Journal of Clinical Investigation, Vol. 128, No. 12, 03.12.2018, p. 5307-5321.

Research output: Contribution to journalArticle

Chernikova, SB, Nguyen, RB, Truong, JT, Mello, SS, Stafford, JH, Hay, MP, Olson, A, Solow-Cordero, DE, Wood, DJ, Henry, S, von Eyben, R, Deng, L, Gephart, MH, Aroumougame, A, Wiese, C, Game, JC, Győrffy, B & Martin Brown, J 2018, 'Dynamin impacts homology-directed repair and breast cancer response to chemotherapy', Journal of Clinical Investigation, vol. 128, no. 12, pp. 5307-5321. https://doi.org/10.1172/JCI87191
Chernikova SB, Nguyen RB, Truong JT, Mello SS, Stafford JH, Hay MP et al. Dynamin impacts homology-directed repair and breast cancer response to chemotherapy. Journal of Clinical Investigation. 2018 Dec 3;128(12):5307-5321. https://doi.org/10.1172/JCI87191
Chernikova, Sophia B. ; Nguyen, Rochelle B. ; Truong, Jessica T. ; Mello, Stephano S. ; Stafford, Jason H. ; Hay, Michael P. ; Olson, Andrew ; Solow-Cordero, David E. ; Wood, Douglas J. ; Henry, Solomon ; von Eyben, Rie ; Deng, Lei ; Gephart, Melanie Hayden ; Aroumougame, Asaithamby ; Wiese, Claudia ; Game, John C. ; Győrffy, Balázs ; Martin Brown, J. / Dynamin impacts homology-directed repair and breast cancer response to chemotherapy. In: Journal of Clinical Investigation. 2018 ; Vol. 128, No. 12. pp. 5307-5321.
@article{082f5d7e100447aabe6516d6989fae22,
title = "Dynamin impacts homology-directed repair and breast cancer response to chemotherapy",
abstract = "After the initial responsiveness of triple-negative breast cancers (TNBCs) to chemotherapy, they often recur as chemotherapy-resistant tumors, and this has been associated with upregulated homology-directed repair (HDR). Thus, inhibitors of HDR could be a useful adjunct to chemotherapy treatment of these cancers. We performed a high-throughput chemical screen for inhibitors of HDR from which we obtained a number of hits that disrupted microtubule dynamics. We postulated that high levels of the target molecules of our screen in tumors would correlate with poor chemotherapy response. We found that inhibition or knockdown of dynamin 2 (DNM2), known for its role in endocytic cell trafficking and microtubule dynamics, impaired HDR and improved response to chemotherapy of cells and of tumors in mice. In a retrospective analysis, levels of DNM2 at the time of treatment strongly predicted chemotherapy outcome for estrogen receptor–negative and especially for TNBC patients. We propose that DNM2-associated DNA repair enzyme trafficking is important for HDR efficiency and is a powerful predictor of sensitivity to breast cancer chemotherapy and an important target for therapy.",
author = "Chernikova, {Sophia B.} and Nguyen, {Rochelle B.} and Truong, {Jessica T.} and Mello, {Stephano S.} and Stafford, {Jason H.} and Hay, {Michael P.} and Andrew Olson and Solow-Cordero, {David E.} and Wood, {Douglas J.} and Solomon Henry and {von Eyben}, Rie and Lei Deng and Gephart, {Melanie Hayden} and Asaithamby Aroumougame and Claudia Wiese and Game, {John C.} and Bal{\'a}zs Győrffy and {Martin Brown}, J.",
year = "2018",
month = "12",
day = "3",
doi = "10.1172/JCI87191",
language = "English (US)",
volume = "128",
pages = "5307--5321",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "12",

}

TY - JOUR

T1 - Dynamin impacts homology-directed repair and breast cancer response to chemotherapy

AU - Chernikova, Sophia B.

AU - Nguyen, Rochelle B.

AU - Truong, Jessica T.

AU - Mello, Stephano S.

AU - Stafford, Jason H.

AU - Hay, Michael P.

AU - Olson, Andrew

AU - Solow-Cordero, David E.

AU - Wood, Douglas J.

AU - Henry, Solomon

AU - von Eyben, Rie

AU - Deng, Lei

AU - Gephart, Melanie Hayden

AU - Aroumougame, Asaithamby

AU - Wiese, Claudia

AU - Game, John C.

AU - Győrffy, Balázs

AU - Martin Brown, J.

PY - 2018/12/3

Y1 - 2018/12/3

N2 - After the initial responsiveness of triple-negative breast cancers (TNBCs) to chemotherapy, they often recur as chemotherapy-resistant tumors, and this has been associated with upregulated homology-directed repair (HDR). Thus, inhibitors of HDR could be a useful adjunct to chemotherapy treatment of these cancers. We performed a high-throughput chemical screen for inhibitors of HDR from which we obtained a number of hits that disrupted microtubule dynamics. We postulated that high levels of the target molecules of our screen in tumors would correlate with poor chemotherapy response. We found that inhibition or knockdown of dynamin 2 (DNM2), known for its role in endocytic cell trafficking and microtubule dynamics, impaired HDR and improved response to chemotherapy of cells and of tumors in mice. In a retrospective analysis, levels of DNM2 at the time of treatment strongly predicted chemotherapy outcome for estrogen receptor–negative and especially for TNBC patients. We propose that DNM2-associated DNA repair enzyme trafficking is important for HDR efficiency and is a powerful predictor of sensitivity to breast cancer chemotherapy and an important target for therapy.

AB - After the initial responsiveness of triple-negative breast cancers (TNBCs) to chemotherapy, they often recur as chemotherapy-resistant tumors, and this has been associated with upregulated homology-directed repair (HDR). Thus, inhibitors of HDR could be a useful adjunct to chemotherapy treatment of these cancers. We performed a high-throughput chemical screen for inhibitors of HDR from which we obtained a number of hits that disrupted microtubule dynamics. We postulated that high levels of the target molecules of our screen in tumors would correlate with poor chemotherapy response. We found that inhibition or knockdown of dynamin 2 (DNM2), known for its role in endocytic cell trafficking and microtubule dynamics, impaired HDR and improved response to chemotherapy of cells and of tumors in mice. In a retrospective analysis, levels of DNM2 at the time of treatment strongly predicted chemotherapy outcome for estrogen receptor–negative and especially for TNBC patients. We propose that DNM2-associated DNA repair enzyme trafficking is important for HDR efficiency and is a powerful predictor of sensitivity to breast cancer chemotherapy and an important target for therapy.

UR - http://www.scopus.com/inward/record.url?scp=85058269858&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058269858&partnerID=8YFLogxK

U2 - 10.1172/JCI87191

DO - 10.1172/JCI87191

M3 - Article

C2 - 30371505

AN - SCOPUS:85058269858

VL - 128

SP - 5307

EP - 5321

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -